Nello Mainolfi, Kymera Therapeutics CEO
January 4, 2024 07:00 AM ESTUpdated 09:50 AM
R&D

Kymera dou­bles down on pro­tein de­graders for im­munol­o­gy, chas­ing Dupix­ent and So­tyk­tu

Ryan Cross

Senior Science Correspondent

Look­ing to fur­ther ex­pand the reach of pro­tein de­graders be­yond can­cer, Kymera Ther­a­peu­tics re­vealed two new pro­grams Thurs­day morn­ing that it hopes will com­pete with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times